花生过敏口服免疫治疗(PACE):疗效与安全性的系统评价与Meta分析
该系统评价与Meta分析纳入12项随机对照试验(n=1041,中位年龄8.7岁),比较花生口服免疫治疗与回避或安慰剂。口服免疫治疗增加过敏性反应和肾上腺素使用风险,但更可能通过监督下激发试验;生活质量无差异。
要点
- 口服免疫治疗较回避/安慰剂增加过敏性反应风险(RR 3.12,95%CI 1.76-5.55,高确定性)。
- 口服免疫治疗增加肾上腺素使用(RR 2.21,95%CI 1.27-3.83,高确定性)。
- 口服免疫治疗更可能通过监督下激发试验(RR 12.42,95%CI 6.82-22.61,高确定性)。
核心结论
- 高确定性证据表明,现有花生口服免疫治疗方案虽有效诱导脱敏,但较回避或安慰剂显著增加过敏性和过敏性反应。
- 需要更安全的花生过敏治疗方法以及评估患者重要结局的严格随机对照试验。
研究设计与样本
- 系统评价与Meta分析(PACE),检索MEDLINE、EMBASE、Cochrane对照试验注册库、拉丁美洲与加勒比健康科学文献、中国知网、WHO临床试验注册平台、美国食品药品监督管理局和欧洲药品管理局数据库,从建库至2018年12月6日,无语言限制。
- 纳入比较口服免疫治疗与无口服免疫治疗(回避或安慰剂)的花生过敏随机对照试验,共12项试验(n=1041;试验中位年龄8.7岁[IQR 5.9-11.2])。
- 采用随机效应模型进行Meta分析,使用GRADE方法评估证据确定性;研究注册号PROSPERO CRD42019117930。
主要发现
- 口服免疫治疗 versus 无口服免疫治疗:过敏性反应风险RR 3.12(95%CI 1.76-5.55),I²=0%,风险差15.1%,高确定性。
- 过敏性反应频率IRR 2.72(95%CI 1.57-4.72),I²=0%,风险差12.2%,高确定性;肾上腺素使用RR 2.21(95%CI 1.27-3.83),I²=0%,风险差4.5%,高确定性;在剂量递增期和维持期相似(交互作用P=0.92)。
- 严重不良事件RR 1.92(95%CI 1.00-3.66),I²=0%,风险差5.7%,中等确定性。
- 非过敏性反应:呕吐RR 1.79(95%CI 1.35-2.38),I²=0%,高确定性;血管性水肿RR 2.25(95%CI 1.13-4.47),I²=0%,高确定性;上呼吸道反应RR 1.36(95%CI 1.02-1.81),I²=0%,中等确定性;下呼吸道反应RR 1.55(95%CI 0.96-2.50),I²=28%,中等确定性。
- 通过监督下激发试验(防止院外反应的替代指标)的可能性:口服免疫治疗组更高,RR 12.42(95%CI 6.82-22.61),I²=0%,风险差36.5%,高确定性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral immunotherapy is an emerging experimental treatment for peanut allergy, but its benefits and harms are unclear. We systematically reviewed the efficacy and safety of oral immunotherapy versus allergen avoidance or placebo (no oral immunotherapy) for peanut allergy. METHODS: In the Peanut Allergen immunotherapy, Clarifying the Evidence (PACE) systematic review and meta-analysis, we searched MEDLINE, EMBASE, Cochrane Controlled Register of Trials, Latin American & Caribbean Health Sciences Literature, China National Knowledge Infrastructure, WHO's Clinical Trials Registry Platform, US Food and Drug Administration, and European Medicines Agency databases from inception to Dec 6, 2018, for randomised controlled trials comparing oral immunotherapy versus no oral immunotherapy for peanut allergy, without language restrictions. We screened studies, extracted data, and assessed risk of bias independently in duplicate. Main outcomes included anaphylaxis, allergic or adverse reactions, epinephrine use, and quality of life, meta-analysed by random effects. We assessed certainty (quality) of evidence by the GRADE approach. This study is registered with PROSPERO, number CRD42019117930. RESULTS: 12 trials (n=1041; median age across trials 8·7 years [IQR 5·9-11·2]) showed that oral immunotherapy versus no oral immunotherapy increased anaphylaxis risk (risk ratio [RR] 3·12 [95% CI 1·76-5·55], I2=0%, risk difference [RD] 15·1%, high-certainty), anaphylaxis frequency (incidence rate ratio [IRR] 2·72 [1·57-4·72], I2=0%, RD 12·2%, high-certainty), and epinephrine use (RR 2·21 [1·27-3·83], I2=0%, RD 4·5%, high-certainty) similarly during build-up and maintenance (pinteraction=0·92). Oral immunotherapy increased serious adverse events (RR 1·92 [1·00-3·66], I2=0%, RD 5·7%, moderate-certainty), and non-anaphylactic reactions (vomiting: RR 1·79 [95%CI 1·35-2·38], I2=0%, high-certainty; angioedema: 2·25 [1·13-4·47], I2=0%, high-certainty; upper tract respiratory reactions: 1·36 [1·02-1·81], I2=0%, moderate-certainty; lower tract respiratory reactions: 1·55 [0·96-2·50], I2=28%, moderate-certainty). Passing a supervised challenge, a surrogate for preventing out-of-clinic reactions, was more likely with oral immunotherapy (RR 12·42 [95% CI 6·82-22·61], I2=0%, RD 36·5%, high-certainty). Quality of life was not different between groups (combined parents and self report RR 1·21 [0·87-1·69], I2=0%, RD 0·03%, low-certainty). Findings were robust to IRR, trial sequential, subgroup, and sensitivity analyses. INTERPRETATION: In patients with peanut allergy, high-certainty evidence shows that available peanut oral immunotherapy regimens considerably increase allergic and anaphylactic reactions over avoidance or placebo, despite effectively inducing desensitisation. Safer peanut allergy treatment approaches and rigorous randomised controlled trials that evaluate patient-important outcomes are needed. FUNDING: None.
引用
- Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet. 2019. PMID: 31030987. doi:10.1016/S0140-6736(19)30420-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。